Mircette

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mircette

Mircette is a specific trade name for a prescription-only medication, indicated solely for the prevention of pregnancy in women who choose this method of contraception. It belongs to the high-level pharmacological class of Hormonal Contraceptives, specifically as a Combined Oral Contraceptive (COC) because it incorporates two different types of synthetic hormones.

Property Description
Active ingredients Desogestrel, Ethinyl Estradiol
Form Oral Tablets
Pharmacological class Hormonal Contraceptives (Combined Oral Contraceptive)
Common use Prevention of pregnancy (Contraception)
Origin Synthetic

Mircette's Identity: A Combined Oral Contraceptive (COC)

Mircette is a hormonal medication, synthetic in origin, designed for oral administration in the form of tablets. Its classification as a combination product is clinically recognized for providing effective contraception. This medicine is categorized as a COC due to the inclusion of both an estrogenic and a progestogenic component in its formulation.

Composition and Type: Distinctive Hormone Regimen

The core active ingredients [INN] are Desogestrel and Ethinyl Estradiol, both synthesized compounds. Ethinyl Estradiol is the estrogen component, while Desogestrel functions as a prodrug that is metabolized rapidly in vivo to its highly active form, Etonogestrel. This synthetic progestogen belongs to the third-generation progestins. A distinctive feature of this particular regimen is the inclusion of both hormone-containing active tablets and a reduced number of hormone-free inert tablets, a modification that shortens the length of the usual hormone-free interval.

High-Level Purpose and Mechanism Principle

The high-level purpose of Mircette is to provide effective contraception through hormonal regulation. The primary mechanism relies on the inhibition of ovulation, preventing the monthly release of an egg. This central action is fortified by secondary effects, specifically changes in the cervical mucus and modifications to the uterine lining, which serve as protective barriers against fertilization and implantation.

Regulatory References

  1. Combination birth control pills (MedlinePlus)
  2. Mechanism of Action of Combined Hormonal Contraceptives (NIH)

What side effects are possible with Mircette?

Possible Side Effects and Safety Information

The safety profile for Mircette (desogestrel/ethinyl estradiol and ethinyl estradiol) is structured around the potential for serious, but rare, events and the occurrence of more common, less severe reactions.


Serious Adverse Reactions

The most serious documented risks involve vascular and thrombotic events. These include an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (heart attack), and stroke (cerebral thrombosis). The risk of developing venous thromboembolic disease is highest during the first year of use. The medication is officially contraindicated in women over the age of 35 who smoke cigarettes, as this significantly increases the risk of serious cardiovascular events.

Other serious documented safety concerns include the risk of hepatic neoplasia, specifically the development of benign liver tumors (hepatic adenomas) and, rarely, malignant tumors (hepatocellular carcinoma), with risk increasing with duration of use. The medication is also contraindicated in individuals with active liver disease, a history of liver tumors, or uncontrolled hypertension.

Common Adverse Reactions

The most frequently reported adverse reactions from clinical studies are classified as common (occurring in 1% to 10% of users). These include:

System-Organ Class Common Reactions (1%–10%)
Gastrointestinal Nausea, abdominal pain, vomiting, diarrhea
Nervous System Headache, dizziness, migraine
Psychiatric Depressed mood, altered mood, nervousness
Other Breast pain, increased weight, fluid retention

Breakthrough bleeding and spotting are also commonly experienced, especially during the initial cycles of use. Should any changes in vision, new-onset severe headaches, or symptoms of a blood clot or liver problem (such as jaundice) occur, the regulatory documents advise discontinuing use and seeking immediate medical evaluation. The medication is also contraindicated during pregnancy and while breastfeeding, as it may decrease milk production.

Overdose and Emergency Response

Mircette Overdose and When to Seek Help

The official regulatory documentation addressing the acute ingestion of large doses of Mircette outlines specific expected clinical signs and required emergency actions. The documented clinical course of over-ingestion is generally considered low-risk.

Documented Overdose Manifestations

System Affected Officially Documented Signs
Gastrointestinal Nausea and Vomiting
Reproductive (Female) Withdrawal bleeding (metrorrhagia)

The official overdose profile states that the acute ingestion of large, excess doses of the combined oral contraceptive is typically not associated with severe or life-threatening outcomes. Regulatory sources emphasize that no serious harmful effects are anticipated.

Mandated Emergency Actions and Management

Immediate medical attention must be sought if an overdose is suspected or if unexpected severe signs, such as passing out or having trouble breathing, occur. Official instructions require contacting a Poison Control Center or getting medical help right away for guidance regarding the suspected over-ingestion.

The management of overdose is strictly symptomatic and supportive, as regulatory documents confirm that no specific antidote is known for an overdose involving desogestrel and ethinyl estradiol. A population-specific consideration noted in the labeling is the potential for slight vaginal bleeding in pre-pubescent females who ingest the medication.

Therapeutic Uses of Mircette

What Mircette Treats: Main Uses and Benefits

Mircette’s active ingredients are commonly used for fertility status regulation to help with the prevention of pregnancy in women of reproductive age. This generally represents the primary therapeutic focus for which the medication is intended.

Symptom Management for Menstrual Discomfort and Volatility

The medication is commonly applied across domains where additional symptomatic support is needed to ease the burden associated with heavy menstrual bleeding, pronounced menstrual pain and cramping, and moderate hormonal acne. It is used for managing symptom clusters that may become intense or disruptive.

“This supportive role contributes to patients coping more steadily with symptom fluctuations throughout the cycle.”

This supportive benefit contributes to improved comfort and the establishment of predictable, lighter periods, assisting with maintaining functional stability when symptoms intensify.


Quick Fact: Relief for Menstrual Discomfort Mircette may be part of symptomatic management applied to ease the burden of dysmenorrhea (painful periods) and menorrhagia (heavy bleeding), in addition to its use in contraception.


Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Mircette Use

Mircette is officially indicated for use in females of reproductive potential for the prevention of pregnancy. Use is generally established in post-menarche adolescents and adult women. The medicine is not indicated for use in elderly women, and use is not recommended before the start of menstruation.

Absolute Contraindications

Official regulatory labeling dictates that Mircette must not be used by populations with specific high-risk conditions. These groups are considered contraindicated:

Population Group
Women over 35 years of age who smoke
Individuals with a current or past history of thromboembolic disorders (e.g., blood clots, stroke, heart attack)
Known or suspected breast cancer or other estrogen-dependent tumors
Active liver disease or liver tumors
Severe migraine headaches with aura
Current or suspected pregnancy

Restricted and Non-Recommended Use

Use is not recommended in women who are breastfeeding due to the passage of hormones into breast milk. Initiation of the medicine is advised no earlier than four weeks postpartum for non-breastfeeding women. The medicine must also be discontinued at least four weeks before and for two weeks after major surgery or during prolonged immobilization.

What should I know about interactions with other medicines?

This section outlines documented interactions based on official regulatory labeling.

Interacting Medicinal Products and Substances

Interaction Type Interacting Categories/Products Resulting Constraint
Reduced Efficacy Risk Certain Anticonvulsants (e.g., phenytoin, carbamazepine, barbiturates), Rifampin, Griseofulvin, Bosentan, and the herbal product St. John's wort Co-administration may reduce the concentration of Mircette's components, which can compromise the medicine's effectiveness. Backup contraception is often required during and for a period after stopping the interacting drug.
Increased Risk/Toxicity Hepatitis C combination products (e.g., ombitasvir/paritaprevir/ritonavir with or without dasabuvir), Tizanidine, and Lamotrigine Co-administration is generally contraindicated with certain Hepatitis C regimens due to risk of liver enzyme elevations. This medicine may increase the plasma concentrations of Tizanidine and Lamotrigine, requiring monitoring.
Food/Beverage Grapefruit Juice May increase the plasma concentrations of the estrogen component, potentially raising the risk of adverse effects.

Interaction-Related Restrictions

Official labeling strictly contraindicates the use of this medicine in women over 35 years of age who smoke tobacco due to a significant increase in the risk of serious cardiovascular events. The medicine is also known to interfere with the results of certain laboratory tests, including those for blood clotting factors and thyroid function. These interactions reflect the known metabolic pathways of the drug's hormonal components.

Mechanism of Action

Central Suppression of the Hypothalamic-Pituitary-Ovarian (HPO) Axis

The physiological effects of Mircette are achieved through a synchronized, two-pronged hormonal approach targeting central neuroendocrine systems and peripheral reproductive tract tissues. The primary mechanism involves the synthetic estrogen (Ethinyl Estradiol) and progestogen (Etonogestrel) acting as agonists on their respective hormone receptors in the hypothalamus and pituitary gland. This action intensifies the negative feedback signal, resulting in the suppression of key reproductive hormones FSH and LH, thereby preventing the critical LH surge. The direct physiological consequence of this is the inhibition of ovulation, a process characterized by the suppression of the oocyte's release from the ovary.

Peripheral Modification and Mechanistic Synergy

Concurrently, the progestogen modulates peripheral tissues. This action increases the viscosity and thickness of the cervical mucus, altering the environment for sperm motility. Furthermore, the estrogen component contributes to the overall suppressive activity by increasing the number of progesterone receptors in target tissues. This synergy induces structural and cellular changes in the endometrial lining.

Dosage and Administration Information

Mircette is intended solely for oral administration and is utilized according to a fixed, continuous 28-day cyclical regimen. This regimen is defined as a sequential course delivered via a single blister pack of tablets. Adherence to a once daily frequency at the same time every day is a core procedural requirement for proper administration.

The standardized regimen is composed of three distinct tablet types taken sequentially. The cycle begins with 21 days of the combination tablet, each containing 0.15 mg desogestrel and 0.02 mg ethinyl estradiol. This phase is followed by a transitional period of two days, during which a tablet containing only 0.01 mg ethinyl estradiol is administered. The cycle concludes with five days of an inert (hormone-free) tablet.

All tablets must be consumed in the exact order printed on the packaging to follow the prescribed three-phase sequence and maintain the correct reduced hormone-free interval. Following the completion of the final inert tablet, a new 28-day pack must be started immediately on the next day. Administration options include the initiation of the cycle via either a Day 1 Start or a Sunday Start method. The overall protocol emphasizes that continuous, timely intake is essential, and that tablet intake should not be skipped or delayed by more than 24 hours.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mircette

The research evidence overview for Mircette (desogestrel / ethinyl estradiol) describes the clinical evaluation, the measured outcomes, and what remains to be fully characterized in scientific studies.


Evidence for Use in Pregnancy Prevention (Contraception)

Evidence for preventing pregnancy includes large, multi-site Phase 3 clinical trials examining the primary outcome related to contraception, measured using the Pearl Index (a calculated measure of unintended pregnancies). Studies reported favorable outcomes when the medicine was observed to be used perfectly. Most pivotal trials had follow-up durations limited to 13 to 18 menstrual cycles, meaning long-term measured outcomes spanning many years are primarily supported by broader observational data and post-marketing surveillance.


Research on Cycle Characteristics and Symptom Management

Research has explored the medicine's influence on the overall characteristics of the menstrual cycle, monitoring metrics such as cycle regularity, predictability, total blood loss, and patterns of unscheduled bleeding. Studies documented that regular withdrawal bleeding patterns developed, and unscheduled bleeding generally lessened over time.

Dedicated exploratory studies also examined outcomes related to physical discomfort, such as changes in pain severity scores in women with primary dysmenorrhea (painful periods). This evidence is limited by modest sample sizes and restricted follow-up durations for the symptomatic management aspect.


What Remains Uncertain and Areas for Future Research

A key research limitation is the difference between outcomes observed in studies (perfect use) versus the outcomes seen in typical use settings. Long-term effects beyond 18 months are not fully established from dedicated prospective trials. Furthermore, data for certain groups, such as women with specific co-existing health conditions, or comparative evidence against all newly approved contraceptive methods are not fully characterized.

Frequently Asked Questions (FAQ)

Common questions about Mircette (FAQ)


Q: How quickly does Mircette start working to prevent pregnancy?

According to official product information, the medication is generally considered effective as a contraceptive after seven consecutive days of taking the active tablets. Regulatory guidance advises that a non-hormonal form of backup contraception is used during the initial seven days of the first cycle until effectiveness is established.

Q: What is the difference between Mircette and a progesterone-only pill (mini-pill)?

Mircette is classified as a Combined Oral Contraceptive (COC) because it incorporates two types of synthetic hormones: an estrogen (ethinyl estradiol) and a progestin (desogestrel). By contrast, a progesterone-only pill, sometimes called a mini-pill, contains only a progestin component.

Q: Is Mircette considered a monophasic, biphasic, or triphasic oral contraceptive?

Mircette is not a traditional monophasic pill, as the active tablets contain different hormone dose combinations across the 28-day cycle. Due to this variation, the regimen is sometimes classified as a form of biphasic or similar multi-dose oral contraceptive.

Q: Does Mircette also offer benefits for conditions other than contraception?

In addition to preventing pregnancy, studies have examined the medication’s influence on menstrual cycle characteristics. Evidence suggests that Mircette may lead to more regular cycles, decreased total blood loss, and may lessen the severity of painful periods, known as primary dysmenorrhea.

Q: What is the significance of the 21 active and 7 inactive pills in the Mircette pack?

The regimen is structured to provide a continuous, multi-phase hormone supply. The design includes a phase of low-dose estrogen and inert tablets, resulting in a specific hormone-free interval that is intended to help mitigate symptoms sometimes associated with hormone withdrawal.

Q: Can Mircette be taken by women who are over the age of 35?

Official documents indicate that use is absolutely contraindicated for women over 35 who smoke tobacco due to a significantly increased risk of serious cardiovascular events. For healthy, non-smoking women, the official product labeling and clinical considerations generally focus on the use of the lowest possible effective dose.

Q: How does Mircette compare to other birth control pills in terms of the type of progestin it contains?

Mircette contains desogestrel, a synthetic hormone classified as a third-generation progestin. Regulatory reviews note that evidence from some studies suggests that third-generation COCs may carry a slightly different risk profile for venous thromboembolism (blood clots) than certain second-generation COCs.

Q: Is it possible for the side effects of Mircette to improve or go away after the first few months?

Official patient information states that common initial side effects, such as breakthrough bleeding and spotting, often improve or resolve over time. These symptoms typically lessen or stop within the first few months, usually by the third cycle of use.

Q: Can Mircette be associated with changes in sex drive or libido?

Adverse reaction data from post-marketing experience includes reports of changes in libido. Both a libido decrease and a libido increase have been reported as potential side effects associated with the medication.

Q: Does Mircette have an effect on acne or skin condition?

Regulatory adverse reaction data lists acne as a possible side effect of the medication.

Q: Can Mircette use lead to an increase in blood pressure?

High blood pressure has been reported with this class of medicine, and this is noted in official warnings. Official warnings advise that blood pressure should be regularly monitored while taking this class of medicine.

Q: Is there a risk of developing melasma (darkened skin patches) while taking Mircette?

Official warnings state there is a risk of developing melasma (patchy darkening of the skin), which may be persistent. Official warnings advise that sun protection is an important measure to minimize the risk of developing melasma.

Q: Is Mircette effective immediately if started on the first day of a menstrual period?

Regardless of the start day chosen for the cycle, official guidance states the medication is generally considered effective as a contraceptive only after seven consecutive days of taking the active tablets.

Q: What general expectations should a patient have regarding their period while taking Mircette?

Patients should generally expect their withdrawal bleed (period) to occur during the fourth week of the pill pack. This is the time when the low-dose estrogen and inert tablets are being taken.

Q: Why might a period be missed or unusually light when taking Mircette?

The medication's mechanism modifies the uterine lining, which commonly results in a lighter than usual withdrawal bleed. If a period is missed, particularly when pills were not taken exactly as directed, official patient guidance recommends ruling out pregnancy.

Q: How does Mircette affect future fertility after a person stops taking it?

Post-marketing adverse event data includes reports of temporary infertility after discontinuation of the medication. This is generally an expected temporary effect that should resolve.

Q: Does Mircette protect against sexually transmitted infections (STIs)?

No. Official safety information explicitly states that the medication does not provide protection against HIV, AIDS, or any other sexually transmitted infections (STIs).

Q: Can taking Mircette make it difficult to wear contact lenses?

Official safety information advises consulting an eye care professional if a patient experiences difficulties in wearing contact lenses or notices any changes in their vision while taking the medication.

Q: Is the hormone dose in Mircette considered low-dose compared to other combination pills?

The combination tablets contain an estrogen component that is generally considered to be among the lower dosages available in combined oral contraceptives. The regimen is typically classified as a low-dose option.

Q: How often are follow-up visits or tests typically recommended while taking Mircette?

Patient guidance indicates that routine check-ups are typically required every 6 to 12 months. These visits are intended to monitor the patient's progress and check factors such as blood pressure, consistent with standard medical monitoring guidelines.

Q: Is Mircette available in a generic formulation?

Yes, a lower-cost generic formulation containing desogestrel and ethinyl estradiol is available.

Q: What distinguishes Mircette from its brand name equivalents or generics?

The distinguishing characteristic of this formulation is the unique 28-day regimen. This cycle includes a specific sequence of active combination tablets, followed by two days of low-dose estrogen-only tablets, and finally the inert tablets.

Q: Does Mircette affect cholesterol or blood sugar levels?

Combined oral contraceptives, including this medication, may raise blood sugar and triglyceride (fat) levels. Official warnings note that for individuals with pre-existing conditions like diabetes or high cholesterol, regular monitoring of these metabolic levels may be required.

Q: Is it a concern if vomiting or severe diarrhea occurs shortly after taking an active Mircette pill?

Yes, vomiting or severe diarrhea that occurs within three to four hours of taking an active tablet is a concern because it can affect the absorption of the pill. Procedural instructions are provided in the official documentation for how to handle potential missed doses that may result from severe diarrhea or vomiting, and the need for backup contraception is often noted.

How should Mircette be stored and disposed of?

Storage Requirements

Mircette (desogestrel/ethinyl estradiol and ethinyl estradiol) tablets must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be kept out of the reach of children, as explicitly stated in the official labeling.

Condition Requirement
Temperature 20 C to 25 C (Excursions: 15 C to 30 C)
Child Safety Keep out of the reach of children

Disposal Instructions

Unused or expired Mircette should be disposed of by utilizing a drug take-back program or mail-back service where available. If no take-back program is accessible, the medication must be discarded according to specific FDA guidelines for household disposal, which includes mixing the tablets with an unappealing substance and placing the mixture in a sealed container. The medication must not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mircette found in:

A-Z Index: